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Abstract
Rationale Evidence suggests interactive effects of the tea
components caffeine and L-theanine on behaviour, yet no data
exists exploring the impact of the two on cerebral blood flow
(CBF).
Objectives The current placebo-controlled, double-blind,
counterbalanced, crossover study examined the effects of caf-
feine and L-theanine on CBF and extended previous cognitive
and mood findings by using lower doses than previous studies
of a similar methodology, which more closely reflect the ratios
present in tea.
Methods Twelve habitual consumers and 12 non-habitual
consumers of caffeine each received 75 mg caffeine,
50 mg L-theanine, 75 mg caffeine plus 50 mg L-theanine,
and placebo in a counterbalanced order across four separate
visits. CBF was measured via near-infrared spectroscopy with
cognition and mood assessed at baseline and 30 min post-
dose. Salivary caffeine and peripheral haemodynamics were
co-monitored.
Results Caffeine reduced oxygenated haemoglobin (oxy-Hb),
increased deoxygenated haemoglobin (deoxy-Hb), improved
performance on attention tasks and increased overall mood
ratings. Increases in deoxy-Hb following caffeine were more
pronounced in non-consumers. Some evidence for increased
deoxy-Hb remained when caffeine was combined with L-
theanine, but this effect was attenuated and the effects of caf-
feine on oxy-Hb, cognition and mood were eradicated.
Conclusions Combining L-theanine with caffeine, at levels
and ratios equivalent to one to two cups of tea, eliminated
the vasoconstrictive effect and behavioural effects of caffeine.
This supports previous findings of an interaction between the-
se substances, despite a lack of effects of L-theanine in isola-
tion. However, at the levels tested here, this did not lead to a
positive impact on behaviour.
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Introduction
Caffeine is the most widely consumed psychoactive substance
in the world, with coffee and tea representing our main dietary
sources (Fredholm et al. 1999). The mechanism by which
caffeine exerts its effects is now largely accepted to be through
non-selective antagonism of adenosine A1 and A2A receptors
(Fredholm et al. 1999), with A1 receptors being more closely
related to neural activation and A2A receptor antagonism lead-
ing to vascular effects, including vasoconstriction and a reduc-
tion in cerebral blood flow (CBF) (Dunwiddie and Masino
2001). Functional MRI (fMRI) studies have identified that
both actions can modulate the blood-oxygenation-level depen-
dent (BOLD) signal response and that the ratio of adenosine
receptors (A1 to A2A) influences the overall vascular and neural
effects (Chen and Parrish 2009a; Laurienti et al. 2003), with
upregulation ofA1 receptors observed following chronic caffeine
use (Johansson et al. 1993; Shi and Daly 1999). Caffeine has
been shown to reduce cerebral blood velocity and CBF assessed
using a number of different techniques (Chen and Parrish 2009b;
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Hasse et al. 2005; Kennedy and Haskell 2011; Laurienti et al.
2003; Mathew and Wilson 1991; Rack-Gomer et al. 2009). A
linear dose relationship has been observed between reductions in
CBF and caffeine following doses of 1, 2.5 and 5mg/kg caffeine
(Chen and Parrish 2009a). Effects of caffeine on CBF are also
dependent upon the level of caffeine habitually consumed. In a
withdrawn state, habitual high consumers exhibit higher rest-
ing CBF as compared to low consumers, and caffeine use is
significantly positively correlated with CBF following both
placebo and caffeine (Addicott et al. 2009; Field et al. 2003).
There is also evidence that, despite higher CBF overall, high
consumers exhibit a greater acute reduction in CBF than low
consumers in response to a 250 mg dose of caffeine adminis-
tered whilst in a state of withdrawal (Field et al. 2003). The
reduction in CBF following caffeine runs counter to
neurovascular coupling, a complex and poorly understood
sequence of processes, whereby an increase in neuronal acti-
vation leads to an increase in CBF in order to meet, and, in the
case of oxygen, exceed, the metabolic demands presented by
the activation. This process typically results in an increase in
cerebral oxygenated haemoglobin and a corresponding dilu-
tion of deoxygenated haemoglobin. Despite the observed re-
duction in CBF, and therefore decreased supply of metabolic
substrates, caffeine has consistently been shown to improve
reaction times (Childs and de Wit 2006; Haskell et al. 2008;
Smit and Rogers 2000) and alertness (Quinlan et al. 2000;
Rogers 2007). However, debate continues as to whether these
well-established effects are dependent upon withdrawal (e.g.
Heatherley et al. 2005; Rogers et al. 2003) or not (e.g.
Christopher et al. 2005; Haskell et al. 2005). Although the
beneficial effects of caffeine on cognition and mood have
been reported in a number of studies, relatively few studies
have looked at the effects of caffeine in combination with
other compounds (see Haskell et al. 2013 for review), despite
the fact that caffeine is seldom consumed in isolation.
L-theanine is a naturally occurring amino acid found al-
most uniquely in tea (Camellia sinensis), where it co-exists
with caffeine. Its chemical structure is similar to that of the
neurotransmitter glutamic acid (Nathan et al. 2006), and it has
been shown to increase dopamine concentrations in the rat
brain in a dose-dependent manner (Yokogoshi et al. 1998),
and to protect against human neuronal cell death in vitro
(Cho et al. 2008). However, unlike caffeine, research into
the effects of L-theanine in humans is limited. Anxiolytic ef-
fects have been reported, whereby 200mg L-theanine reduced
acute stress responses (subjective perception, heart rate and
salivary immunoglobulin A) induced by a mental arithmetic
task (Kimura et al. 2007), and a 250 mg dose of L-theanine
slowed reaction time on a visual probe task, indicating re-
duced anxiety (Rogers et al. 2008). EEG studies have also
provided some support for these findings with increases in
resting alpha activity observed following 50 mg (Nobre
et al. 2008) and 200 mg L-theanine (Juneja et al. 1999), which
the authors interpret as being indicative of relaxation. A dose
of 250mg of L-theanine has also been shown to decrease tonic
alpha activity during task performance (Gomez-Ramirez et al.
2007, 2009).
In terms of cognitive function, L-theanine in isolation has
been shown to engender decrements in performance (Gomez-
Ramirez et al. 2007; Haskell et al. 2008) or, at best, an absence
of effects (Gomez-Ramirez et al. 2009; Haskell et al. 2008;
Kelly et al. 2008; Owen et al. 2008). However, when admin-
istered together, L-theanine modulates or potentiates the ef-
fects of caffeine. For instance, Haskell et al. (2008) reported
that a number of effects were evident following a combination
of 250 mg L-theanine and 150 mg caffeine that were not
apparent when each treatment was administered alone; these
included increased speed on several tasks, improved semantic
memory and increased alertness. Other studies have employed
lower doses of L-theanine (~100 mg) and caffeine (~50mg) to
explore these effects (Einother et al. 2010; Kelly et al. 2008;
Owen et al. 2008), providing support for the findings from
studies of higher doses, in terms of improved accuracy
(Einother et al. 2010; Kelly et al. 2008; Owen et al. 2008)
and speed (Einother et al. 2010; Owen et al. 2008) on tasks
of attention, and improvements to measures of memory
(Owen et al. 2008). L-theanine has also been shown to
antagonise the physiological effects of caffeine. Rogers et al.
(2008) demonstrated that although systolic and diastolic blood
pressure were significantly higher following the administra-
tion of 250 mg caffeine when compared to placebo or
200 mg L-theanine alone, the combination of the two com-
pounds led to an attenuation of this effect.
A previous study using the dose of caffeine employed here
(75 mg) showed that caffeine significantly reduced total
haemoglobin as measured by near-infrared spectroscopy
(NIRS) (Kennedy and Haskell 2011). Given that co-
administration of L-theanine with caffeine has previously
been demonstrated to attenuate its haemodynamic effects
(Rogers et al. 2008), it remains a possibility that co-
administration may also attenuate the cerebro-vascular effect
of caffeine. The doses of L-theanine/caffeine and the ratios in
which they have been administered in the majority of assess-
ments of these two interventions to date have tended to con-
tain higher levels of L-theanine than caffeine. This is not rep-
resentative of the ratios normally found in tea in our diet,
which tend to be in the region of 2 to 1 in favour of caffeine.
Similarly, the lowest dose of L-theanine explored previously
in terms of behaviour (100 mg) is equivalent to ~4 cups of tea.
The current study aimed to address these issues using NIRS to
measure CBF in the pre-frontal cortex during cognitive task
performance following caffeine and L-theanine, both alone
and in combination. The cohort included both habitual tea
drinking consumers and non-habitual consumers of caffeine
and involved administration of doses and ratios of caffeine
and L-theanine that more closely reflect those present in tea.
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It is predicted that combining caffeine with L-theanine will
enhance effects of caffeine on behaviour whilst diminishing
haemodynamic effects. Effects on behaviour are expected ir-
respective of habitual consumption status, whereas haemody-
namic effects of caffeine may interact with this factor.
Methods
Initial screening
Prior to participation, volunteers were required to provide in-
formed consent and complete an unpublished caffeine con-
sumption questionnaire that has previously been employed
to assess daily level of caffeine intake (Haskell et al. 2005).
Volunteers were recruited to take part in the study if they fell
into one of two pre-defined categories: ‘habitual consumers’
(those who drank tea and consumed more than 150 mg caf-
feine per day) or ‘non-habitual consumers’ (those who con-
sumed less than 60 mg caffeine per day and no more than 2
cups of tea/coffee per week). These cutoffs are designed to
allow the consumption of a 330 ml can of most standard colas
per day in non-habitual consumers and to ensure that habitual
consumers ingested the equivalent of at least three 190 ml
cups of tea per day (Gray 1998). Only non-smoking volun-
teers who were in good health, not currently taking any dietary
supplements or medication (including the contraceptive pill),
were not colour-blind and did not have a history of head trau-
ma, learning difficulties, ADHD, neurological, vascular or
psychiatric illness were recruited to take part in the study.
Design
A double-blind, counter-balanced, within-subjects, placebo-
controlled design was utilised.
Treatment
Participants attended four study visits, at least 48 h apart and,
at each, received one of the following treatments: 75 mg caf-
feine (pharmaceutical grade caffeine powder, Blackburn
Distributions Ltd.), 50 mg L-theanine (Suntheanine, Taiyo
Europe, Germany), 75 mg caffeine and 50 mg of L-theanine
in combination, or placebo. The doses selected roughly equate
to the levels found in two cups of tea. These were chosen in an
attempt to extend previous findings exploring the effects of
100 mg L-theanine (Einother et al. 2010; Kelly et al. 2008;
Owen et al. 2008) whilst more closely reflecting the ratio of L-
theanine to caffeine found in tea. Each treatment was admin-
istered in the form of two capsules in order to mask any taste
differences and to ensure that participants remained blind to
the treatment they had received. The capsules were prepared
and coded by an independent third party who had no further
involvement with the study. The order in which participants
received each treatment was determined by Latin square and
random allocation to treatment order for each group (habitual
consumers and non-habitual consumers).
Participants
Twenty-four healthy young participants (10 males) between
the ages of 18 and 35 (mean age 21.8, standard deviation (SD)
3.19) were recruited. Twelve participants were classified as
habitual consumers (five males; mean age 23.3, SD 3.65)
and 12 as non-habitual consumers (five males; mean age
20.4, SD 1.88). From the self-report caffeine consumption
questionnaire, habitual consumers reported drinking between
163 and 432mg caffeine per day (mean 252.2, SD 74.3). Non-
habitual consumers reported drinking between 0 and 56 mg
caffeine per day (mean 16.7, SD 15.6). With regards to tea
consumption, habitual consumers reported consuming be-
tween 1 and 6 cups per day (mean 3.50, SD 1.46) and non-
habitual consumers reported consuming between 0 and 2 per
week (mean 0.45, SD 0.62). The study was approved by
Northumbria University’s School of Psychology and Sport
Sciences’ ethics committee and was conducted according to
the Declaration of Helsinki (1964).
Salivary caffeine levels
Saliva samples were obtained using salivettes (Sarstedt Ltd).
One sample was taken upon arrival and one immediately fol-
lowing the post-dose cognitive assessment. This was to ensure
overnight caffeine abstinence and to confirm caffeine absorp-
tion following caffeinated treatments (no analysis of post-
treatment caffeine levels was made following placebo or L-
theanine). Once taken, samples were frozen at −20 °C. The
samples were then thawed and the caffeine levels in the saliva
samples were measured using an Emit® Caffeine Assay (Dade
Behring Ltd).
Cognitive and mood assessment
All cognitive and mood measures were delivered using the
Computerised Mental Performance Assessment System
(COMPASS, Northumbria University, Newcastle upon Tyne,
UK), a purpose-designed software application for the flexible
delivery of randomly generated parallel versions of standard
and novel cognitive assessment tasks. This assessment system
has previously been shown to be sensitive to nutritional inter-
ventions (Kennedy et al. 2010a; Stonehouse et al. 2013) in-
cluding caffeine (Kennedy and Haskell 2011). The tasks were
chosen based on their known sensitivity to one or both of the
nutritional interventions under investigation (Haskell et al.
2008; Kennedy and Haskell 2011; Lieberman et al. 1987)
and, in order to correspond with the region of CBF
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measurements, their ability to activate the pre-frontal cortex
(Drummond et al. 1999; Lawrence et al. 2002; Schroeter et al.
2002). The tasks completed at baseline and post-dose were
identical with the exception that baseline tasks were shortened
to 2 min. This ensured that participants were not connected to
NIRS equipment for more than 2 h and therefore minimised
the discomfort associated with restricted movement. Tasks
were presented in the following order (post-dose duration in
parentheses): serial 3 subtractions (4 min), serial 7 subtrac-
tions (4 min), simple reaction time (SRT) (8 min), rapid visual
information processing (RVIP) (8 min), choice reaction time
(CRT) (8 min) and Stroop (8 min).
Serial 3 subtractions
A starting number between 800 and 999 appears on the screen
and participants are instructed to count backwards as quickly
and as accurately as possible from this number in threes, using
the linear number keys to make their response. Responses are
cleared when the ‘enter’ key is pressed. Participants are only
shown one number on screen and the rest of the numbers are
generated by subtracting from the previous number in their
head. In the case of incorrect responses, subsequent responses
are scored positively if they are correct in relation to the new
number. This timed task was scored for total responses and
number of errors.
Serial 7 subtractions
This task is identical to the serial 3s subtraction task
except that it involves the serial subtraction of 7s.
Simple reaction time
An upwards pointing arrow appears on the screen at a random
inter-stimulus duration between 1 and 3.5 s. Participants have
to respond as quickly as they can when they see a stimulus
appear by pressing the space bar. One hundred and ninety
stimuli were presented and the task was scored for reaction
time. Responses below 150 ms do not register for the task.
Rapid visual information processing
The participant monitors a continuous series of digits for tar-
gets of three consecutive odd or three consecutive even digits.
The digits are presented on the computer screen at the rate of
100 per minute in pseudo-random order, and the participant
responds to the detection of a target string by pressing the
space bar as quickly as possible. The task is continuous. The
task was scored for percentage of target strings correctly de-
tected, average reaction time for correct detections, and
number of false alarms.
Choice reaction time
An arrow pointing either left or right is presented in the middle
of the screen at a random inter-stimulus duration between 1 to
3.5 s. As soon as participants see an arrow appear on the
screen, they are required to indicate the direction of the arrow
by pressing left and right keys (‘M’ and ‘Z’ on keyboard). One
hundred and eighty-five stimuli were presented and the task
was scored for percentage of correct responses and reaction
time. Responses below 150 ms do not register.
Stroop
In this task, a series of colour names appear on the screen one
at a time in different coloured fonts. Participants are required
to use a colour-coded response pad to select the colour that
matches the colour font that the word is written in. The words
that are presented are either ‘congruent’ (name of colour and
colour of ink the same) or ‘incongruent’ (name of colour and
colour of ink different) and are presented randomly.
Participants are asked to respond as quickly and as accurately
as possible. This timed task was scored for total responses,
number of errors, reaction time and interference reaction time
(difference in reaction time for congruent and incongruent
stimuli). Responses below 150 ms do not register.
Subjective assessment
Caffeine research visual analogue scales adapted from Rogers
et al. (2003) that have previously been used in caffeine and L-
theanine research were also included (Haskell et al. 2005,
2008; Kennedy and Haskell 2011) and were presented on-
screen. Participants were shown the following descriptors ‘re-
laxed’, ‘alert’, ‘jittery’, ‘tired’, ‘tense’, ‘headache’, ‘overall
mood’ and ‘mentally fatigued’ and asked to rate how much
theymatched their current state by placing an ‘x’ on a 100-mm
line with the end points labelled ‘not at all’ (left hand end) and
‘extremely’ (right hand end), with the exception of ‘overall
mood’, which was labelled ‘very bad’ and ‘very good’. ‘Alert’
and ‘tired’, and ‘tense’ and ‘relaxed’ scores were then com-
bined to create respective factors of ‘alertness’ and ‘tension’ as
recommended by the authors.
Near-infrared spectroscopy measurements
Near infrared spectroscopy (NIRS) is a method of studying
functional activation through monitoring changes in the hae-
modynamic properties of the brain (Huppert et al. 2006). It is a
non-invasive brain imaging technique in which two wave-
lengths of light that are differentially absorbed by oxygenated
and deoxygenated haemoglobin are introduced through the
skull via a laser emitter and measured following transit
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through the upper surface of the cortex, by an optode placed at
a pre-set distance from the light source.
Relative changes in the absorption of near-infrared light
were measured at a time resolution of 10 Hz using a 12-
channel Oxymon system (Artinis Medical Systems B.V.).
The system emitted two nominal wavelengths of light (~780
and 855 nm) with an emitter/optode separation distance of
4 cm. The differential path length factor was adjusted accord-
ing to the age of the participant. Relative concentration chang-
es in oxygenated haemoglobin (oxy-Hb), deoxygenated
haemoglobin (deoxy-Hb) and total haemoglobin (total-Hb)
were calculated by means of a modified Beer–Lambert law
using the proprietorial software. In this study, a simple two
emitter/receiver optode pair configuration was utilised (i.e.
two channels). The emitter/receiver optode pairs were posi-
tioned over the left and right pre-frontal cortex that included
the areas corresponding to the international 10-20 system Fp1
and Fp2 EEG positions. The ability of NIRS to measure blood
flow changes following cerebral activation has been validated
by its use in a number of studies (Fallgatter and Strik 1998;
Izzetoglu et al. 2003, 2004; Schroeter et al. 2002; Shibuya-
Tayoshi et al. 2007) including following different nutritional
interventions (Jackson et al. 2012a, b; Kennedy and Haskell
2011; Kennedy et al. 2010b; Wightman et al. 2014).
Blood pressure and heart rate
Blood pressure and heart rate (Boso-Medicus Prestige;
Bosch+Sohn, Germany) readings were taken from the left
arm following a 5 min seated rest. Readings were taken at
each visit upon arrival and following post-dose completion
of the cognitive tasks.
Procedure
Participants were required to attend the laboratory on five
separate occasions. The first visit was a screening session
where participants were informed about the nature of the
study, its requirements and its restrictions. Written informed
consent was obtained and their eligibility to participate was
confirmed. Habitual caffeine intake and source were assessed
via questionnaire, and familiarisation with the tasks to be ad-
ministered on the study days was conducted. The remaining
four study visits were identical to each other, with the excep-
tion of the treatment administered. On each day, participants
attended the lab at 8 a.m. following an overnight 12-h fast
during which they were only permitted to drink water. Upon
arrival, heart rate and blood pressure readings were taken fol-
lowing 5 min of seated rest. Following a baseline completion
of the mood scales, salivary caffeine levels were taken to
ensure caffeine abstinence. Following this, the NIRS head-
band was fitted. Participants initially sat quietly for 5 min
and then made a baseline completion of the cognitive tasks.
Upon completion of the tasks, participants were required to sit
quietly for a 2 min NIRS resting baseline period. Participants
were then required to take their treatment for the day.
Following a 30 min absorption period (during which time
NIRS recording continued whilst participants watched a
non-stimulating wildlife DVD), participants completed a sec-
ond set of the cognitive tasks and a final rest period (8 min)
(included to allow an assessment of whether any CBF effects
apparent after the absorption period are as a result of increased
neural demand during tasks or are simply due to the time
course of effects of treatment). They then had their blood
pressure and heart rate measured for a second time, rated their
mood for a second time, and gave a second saliva sample,
used to confirm caffeine absorption following caffeinated
treatment (see Fig. 1 for more details of procedure and task
duration). Participants returned for their next study visit within
7 days, following (at least) a 48-h washout period.
Statistics
To assess the possibility of any on-day or consumer status
differences in cognitive performance, mood, blood pressure
and heart rate prior to treatment, two-way repeated measures
ANOVAs were conducted (treatment×consumer status) on
baseline data. Any significant differences were further ex-
plored with Bonferroni-corrected pairwise comparisons.
In order to confirm caffeine absorption for caffeine-
containing treatments (caffeine, combination), a two-way
mixed ANOVAwas conducted (treatment×time) on pre- and
post-caffeine and combination saliva samples.
NIRS data was averaged across 4 min (absorption period)
and 8 min (individual tasks) epochs and baseline adjusted to
the 2 min post-task resting pre-treatment period. To account
for disruption in NIRS readings as a result of consumption of
treatment, the first 2 min of the absorption period was omitted
from the analysis. Data from both channels were averaged for
oxy-Hb and deoxy-Hb and analysed by three-way mixed
ANOVA (epoch×treatment×consumer status). Significant
treatment-related interactions were further investigated by a
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priori planned comparisons where each active treatment was
compared to placebo at each epoch utilising t tests calculated
with the mean squares error from the ANOVA (Keppel 1991).
In order to reduce the potential for type I errors, only those
planned comparisons associated with a statistically significant
difference on the initial ANOVA are reported.
Cognitive performance, subjective mood, heart rate and
blood pressure data were analysed using the MIXED proce-
dure in SPSS 21.0. Themodel included the respective baseline
as a time variant covariate, and fixed effects terms entered into
the model were treatment, consumer, treatment*consumer and
baseline value. Significant effects or interactions (p<0.05)
were further explored with Bonferroni-corrected pairwise
comparisons.
Results
Baseline measures
A significant on-day pre-treatment difference in baseline
Stroop errors [F(3, 66)=3.13, p<0.05] was lost following
Bonferroni correction. There were no other significant on-
day or consumer status differences in cognitive performance,
mood or autonomic measures prior to treatment.
Salivary caffeine levels
All participants adhered to overnight caffeine restriction.
Mean baseline values were 0.34 μg/ml and confirmed over-
night abstinence [levels below 1 μg/ml have previously been
reported for overnight caffeine abstinence (Evans and
Griffiths 1999)]. Following caffeinated treatment, salivary
caffeine levels were 2.25 μg/ml (combination) and
2.33 μg/ml (caffeine). Analysis of the results confirmed that
in comparison to baseline levels, salivary caffeine was signif-
icantly higher following caffeine and combination treatments
[F(1, 23)=63.27, p<0.0001], with no significant difference
between treatments.
Central haemodynamic effects (NIRS)
Oxygenated haemoglobin
A significant interaction effect (epoch×treatment) was ob-
served for oxy-Hb [F(36, 792)=1.503, p<0.05]. Oxy-Hb
was significantly reduced during minutes 3–6 (p<0.05) and
11–18 of the absorption period (p<0.05) and during SRT
(p<0.01), RVIP (p<0.001), CRT (p<0.001) and Stroop tasks
(p<0.001) and the rest period (p<0.001) following caffeine as
compared to placebo. This effect was not evident during cog-
nitive tasks when caffeine was combined with L-theanine, or
when L-theanine was administered alone. Following the
combination, oxy-Hb was significantly increased during mi-
nutes 23–30 of the absorption period as compared to placebo
[minutes 23–26 (p<0.005) and 27–30 (p<0.05)]; see Fig. 2a.
Deoxygenated haemoglobin
A significant interaction effect (epoch×treatment) was also
evinced for deoxy-Hb [F(36, 792)=1.617, p<0.05].
Significant increases were observed during serial subtractions
(p<0.01), SRT (p<0.05), RVIP (p<0.05) and Stroop tasks
(p<0.05) and during the rest period (p<0.05) following caf-
feine as compared to placebo. Following the combination,
deoxy-Hb was significantly increased during serial subtrac-
tions (p<0.05), CRT (p<0.05) and Stroop tasks (p<0.05), as
compared to placebo; see Fig. 2b.
There was also a significant treatment by consumer status
interaction for deoxy-Hb [F(3, 792)=3.250, p<0.05]. Non-
habitual consumers had significantly higher deoxy-Hb
throughout the absorption and task periods following caffeine
as compared to placebo (p<0.005); see Fig 3.
Behavioural effects
Serial 3 subtractions
A significant treatment×consumer status interaction effect on
the total number of serial three subtractions [F(3, 66)=3.40,
p<0.05] was evinced. However, pairwise comparisons re-
vealed no significant differences between treatments.
Choice reaction time
There was a significant main effect of treatment on choice
reaction time [F(3, 66)=4.18, p<0.05]. Reaction time was
significantly faster following caffeine compared to placebo
(p<0.05). There was also a significant consumer status effect
[F(1, 66)=10.08, p<0.005] whereby consumers were found
to be significantly faster than non-habitual consumers, irre-
spective of treatment.
Stroop
There was a significant main effect of treatment on total num-
ber of Stroop responses [F(3, 66)=8.95, p<0.0001]. The num-
ber of responses was significantly higher following caffeine
compared to placebo (p<0.005). There was also a significant
main effect of treatment on Stroop errors [F(3, 66)=3.18,
p<0.05]. Participants produced less errors following L-
theanine as compared to the combination (p<0.05). A main
effect of treatment on Stroop reaction time [F(3, 66)=6.92,
p<0.005] demonstrated significantly faster responses follow-
ing caffeine compared to placebo (p<0.005). There was also a
significant consumer status effect on Stroop reaction time
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interference [F(1, 66)=5.16, p<0.05], whereby habitual con-
sumers showed a greater interference effect than habitual non-
consumers. Unadjusted means and standard error for cogni-
tive parameters can be found in Table 1.
Alert
There was a significant main effect of treatment on alert rat-
ings [F(3, 66)=3.09, p<0.05]. Pairwise comparisons revealed
no significant differences following Bonferroni correction.
Overall mood
There was a significant main effect of treatment on ratings of
mood [F(3, 66)=3.13, p<0.05]. Overall mood ratings were
significantly higher following caffeine as compared to placebo
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Table 1 Unadjusted baseline and post-dose scores for cognitive tasks for each treatment by consumer status
Measure Treatment n Pre-dose baseline score Post-dose score Treatment
effect
Consumer
effect
Treatment×
consumer
interactionConsumers Non-consumers Consumers Non-consumers
Serial 3s total
responses (number)
Placebo 12/12 40.17±4.53 41.08±3.59 79.75±8.70 81.67±7.24 F=1.48
p>0.1
F<1 F=3.40
p=0.04L-theanine 40.58±4.07 42.92±4.36 84.83±7.47 79.50±8.19
Caffeine 42.25±3.25 43.67±5.26 82.33±6.69 85.25±8.05
Combination 40.00±3.24 40.75±3.95 84.58±6.63 83.33±7.17
Serial 3s errors
(number)
Placebo 12/12 1.50±0.42 1.25±0.54 3.92±0.85 3.25±0.79 F=1.12
p>0.1
F<1 F<1
L-theanine 1.58±0.50 1.42±0.51 2.75±0.59 4.08±0.76
Caffeine 2.50±0.65 1.58±0.40 3.58±0.67 3.08±0.60
Combination 2.58±0.51 1.25±0.30 2.67±0.43 2.58±0.54
Serial 7s total
responses (number)
Placebo 12/12 25.08±2.97 25.83±3.47 53.75±5.23 54.08±5.28 F=1.22
p>0.1
F=1.17
p>0.1
F<1
L-theanine 27.00±2.20 24.83±2.86 54.08±4.66 49.33±5.05
Caffeine 25.58±2.29 26.08±2.79 53.83±4.38 51.33±5.71
Combination 26.33±2.05 24.75±2.37 56.42±4.43 51.08±4.41
Serial 7s errors
(number)
Placebo 12/12 1.50±0.40 1.25±0.45 3.67±0.89 3.50±1.15 F<1 F<1 F<1
L-theanine 1.33±0.36 2.50±0.76 2.58±0.53 3.75±1.21
Caffeine 1.67±0.68 2.00±0.54 3.25±0.74 4.00±0.72
Combination 1.58±0.45 2.08±0.70 3.33±0.61 3.58±0.73
SRT (ms) Placebo 12/12 294.00±11.19 326.54±16.59 308.38±11.85 344.09±15.26 F=2.63
p=0.08
F=2.06
p>0.1
F<1
L-theanine 288.71±11.38 329.85±19.73 308.37±11.77 365.31±20.98
Caffeine 304.90±9.96 308.08±9.96 312.21±13.43 320.93±11.26
Combination 290.87±9.64 322.86±24.60 304.60±11.62 340.73±28.58
RVIP accuracy (%) Placebo 12/11 70.83±6.17 62.50±4.30 59.51±6.61 52.70±3.41 F=1.09
p>0.1
F<1 F=1.52
p>0.1L-theanine 68.23±5.63 67.05±4.85 58.33±5.20 56.68±3.80
Caffeine 75.52±7.19 62.50±6.31 62.24±6.61 60.94±4.67
Combination 68.75±8.43 67.05±5.34 64.19±5.87 60.23±5.10
RVIP RT (ms) Placebo 12/11 502.55±18.02 481.36±15.76 513.36±21.03 482.54±11.00 F=1.79
p>0.1
F=2.99
p>0.1
F<1
L-theanine 501.75±18.82 480.70±13.99 511.05±17.77 471.87±13.28
Caffeine 510.43±18.23 487.52±12.51 512.74±18.63 474.19±10.02
Combination 499.29±27.41 471.37±14.31 498.83±17.93 465.15±14.47
RVIP false alarms
(number)
Placebo 12/11 1.58±0.50 2.18±0.52 4.42±0.91 5.45±1.23 F<1 F=1.12
p>0.1
F<1
L-theanine 1.17±0.30 1.73±0.49 3.92±1.18 7.09±2.50
Caffeine 0.83±0.24 1.91±0.49 3.42±0.75 5.36±2.64
Combination 0.83±0.30 1.27±0.38 3.83±0.90 6.45±1.92
CRT accuracy (%) Placebo 12/12 96.17±0.87 96.67±0.79 96.04±0.98 96.08±1.16 F=1.19
p>0.1
F<1 F<1
L-theanine 96.33±0.69 95.33±1.68 96.31±0.88 96.22±0.81
Caffeine 96.83±0.72 94.50±0.82 96.40±1.03 96.26±0.73
Combination 96.50±0.96 95.17±1.19 96.71±0.75 96.40±0.66
CRT (ms) Placebo 12/12 425.90±15.09 437.36±18.00 423.10±15.16 496.86±27.84 F=4.18
p=0.02
F=10.08
p=0.004
F=2.68
p=0.07L-theanine 420.64±10.14 448.00±24.75 420.44±9.84 480.83±25.21
Caffeine 410.14±10.90 453.22±27.21 406.85±11.27 442.59±17.51
Combination 409.81±10.06 428.49±25.41 406.70±9.31 448.55±20.78
Stroop total responses
(number)
Placebo 12/12 73.33±1.16 74.42±1.13 294.00±4.03 290.75±4.67 F=8.95
p<0.001
F<1 F<1
L-theanine 73.42±1.94 72.08±1.97 295.42±4.53 289.33±6.16
Caffeine 73.92±1.00 73.92±1.73 300.17±3.91 299.33±4.59
Combination 74.83±1.06 73.42±1.28 300.00±3.14 297.25±3.27
Stroop errors
(number)
Placebo 12/12 1.33±0.36 2.00±0.51 9.58±3.10 11.00±2.05 F=3.18
p=0.04
F<1 F<1
L-theanine 20.8±0.56 2.33±0.43 8.92±2.62 8.25±1.82
Caffeine 2.50±0.82 3.08±0.79 9.25±3.04 10.83±2.26
Combination 2.00±0.81 1.92±0.62 12.00±4.34 10.42±1.93
Stroop RT (ms) Placebo 12/12 651.67±26.36 628.92±26.50 641.25±22.65 660.33±28.40 F=6.92
p=0.002
F<1 F<1
L-theanine 659.50±49.91 692.92±57.09 637.08±25.40 672.17±40.69
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(p<0.005). Unadjusted means and standard error for mood
parameters can be found in Table 2.
Peripheral haemodynamic effects
Blood pressure and heart rate
Analysis of blood pressure levels revealed a significant main
effect of treatment for systolic [F(3, 66)=5.50, p<0.01] and
diastolic [F(3, 66)=3.37, p<0.05] blood pressure. Following
the combination treatment, systolic blood pressure was signif-
icantly higher as compared to placebo (p<0.05) and L-
theanine (p<0.05). Diastolic blood pressure was also signifi-
cantly higher following the combination in comparison to pla-
cebo (p<0.01). There were no significant effects of treatment
on heart rate. Unadjusted means and standard error for periph-
eral haemodynamic parameters can be found in Table 3.
Discussion
The primary aim of the current study was to assess, for the first
time, the independent and interactive effects of caffeine and L-
theanine on cerebral blood flow. The study also extended pre-
vious cognitive and mood findings of the two substances by
exploring behavioural effects of doses lower than those used
in previous studies of a similar methodology, which more
closely reflect the ratios present in tea. The results here dem-
onstrate that, compared to placebo, caffeine led to a reduction
in oxygenated haemoglobin in the pre-frontal cortex during
minutes 3–6 and 11–18 of the absorption period and during
task performance commencing at 39 min post-dose until the
end of testing. This effect of caffeine was abolished by com-
bining it with L-theanine, despite no effects of L-theanine in
isolation on this measure. The expected reduction in
deoxygenated haemoglobin during the task period was atten-
uated following both of the treatments that contained caffeine,
as compared to placebo. Following caffeine alone, this effect
reached significance during the entire task period with the
exception of CRT, whereas following the combination, this
effect reached significance only during serial subtractions,
CRT and Stroop. In addition, there was a significant treat-
ment×consumer interaction, whereby the effects on deoxy-
genated haemoglobin following caffeine alone were predicat-
ed on an increase in non-habitual consumers throughout the
entire testing session.
The reduction in oxy-Hb in the current study supports find-
ings from previous imaging studies showing decreased CBF
following higher doses of caffeine (Chen and Parrish 2009a;
Rack-Gomer et al. 2009), including in the form of tea
(Vidyasagar et al. 2013), and a reduction in total haemoglobin
observed in a more recent study utilising NIRS that adminis-
tered the same, comparatively low, dose of caffeine as here
(Kennedy and Haskell 2011). Of particular interest, the effects
of caffeine on oxy-Hb, but not deoxy-Hb, were abolished by
co-administration with L-theanine. This pattern of effects is
consistent with those previously observed on blood pressure
by Rogers et al. (2008), showing attenuation of the rise in
blood pressure following caffeine in isolation when it was
combined with L-theanine. Although higher doses of caffeine
and L-theanine were used in that study (250 and 200 mg re-
spectively), the ratio of compounds was more comparable to
those used here than other studies in this area, and the post-
treatment assessment took place within a similar time frame
(45 min post-dose).
The significant increase in deoxy-Hb observed following
caffeine relative to placebo is contrary to the decrease in
deoxy-Hb generally observed during cognitive demand
(Fallgatter and Strik 1998; Izzetoglu et al. 2003, 2004;
Kennedy et al. 2010b; Shibuya-Tayoshi et al. 2007). It is,
Table 1 (continued)
Measure Treatment n Pre-dose baseline score Post-dose score Treatment
effect
Consumer
effect
Treatment×
consumer
interactionConsumers Non-consumers Consumers Non-consumers
Caffeine 633.67±23.40 643.17±40.67 607.83±21.39 613.08±26.12
Combination 615.67±22.50 651.33±31.57 605.67±17.21 622.08±18.30
Stroop interference
RT (ms)
Placebo 12/12 11.33±15.55 12.67±12.96 32.92±7.86 7.92±8.60 F=1.23
p>0.1
F=5.16
p=0.03
F=2.13
p>0.1L-theanine 25.00±15.19 14.17±14.36 43.92±9.26 17.67±4.46
Caffeine 38.67±14.67 28.75±19.31 29.08±9.32 29.00±6.65
Combination 25.08±20.05 28.83±10.99 45.33±7.76 27.08±12.09
Means±SEM values are presented with F and p values from the primary analysis of main effects and treatment×consumer interactions. Significant
measures are shown in bold
SRT simple reaction time, RVIP rapid visual information processing, CRT choice reaction time
Psychopharmacology
however, not unexpected given previously observed
neurovascular uncoupling following caffeine (Laurienti et al.
2003; Mulderink et al. 2002; Perthen et al. 2008). Data from
calibrated (to hypercapnia) BOLD fMRI studies showing that
a high single dose of caffeine (~200 mg+), administered to
habitual consumers, reduces blood flow but increases oxygen
consumption in response to task/stimulation, suggest that this
increase in deoxy-Hb is indicative of neural activation (Chen
and Parrish 2009b; Perthen et al. 2008); this is supported by a
lack of effects on deoxy-Hb during the absorption period.
Laurienti et al. (2002) also showed that the effects of
250 mg caffeine administration on fMRI BOLD were corre-
lated to dietary caffeine use, with high consumers showing
significantly higher signal change than low consumers. A
differential effect of consumer status on deoxy-Hb in the
current study, reflecting a significant increase across tasks
following caffeine in non-habitual consumers only, sug-
gests that the disparity of effects of caffeine on BOLD is
the result of varying deoxy-Hb rather than oxy-Hb re-
sponse. Given the lack of interaction effect on oxy-Hb in
the current study, this may point to a specific tolerance to
the effects on deoxy-Hb in habitual caffeine consumers. As
the effects on deoxy-Hb suggest increased neural activa-
tion in non-consumers, this would indicate an upregulation
of A1 receptors (Laurienti et al. 2003), as has previously
been demonstrated (Johansson et al. 1993).
Table 2 Unadjusted baseline and post-dose ratings for mood for each treatment by consumer status
Measure Treatment n Pre-dose baseline score Post-dose score Treatment
effect
Consumer
effect
Treatment×consumer
interaction
Consumers Non-consumers Consumers Non-consumers
Relaxed (mm) Placebo 12/12 64.75±2.73 63.83±3.64 51.83±5.09 55.33±5.47 F=2.28
p>0.1
F<1 F<1
L-theanine 55.83±5.76 63.50±4.76 56.00±5.57 62.58±4.80
Caffeine 58.83±6.63 62.25±6.10 51.50±5.59 54.42±7.35
Combination 61.17±4.24 67.92±4.64 54.75±6.32 64.42±4.91
Alert (mm) Placebo 12/12 57.17±5.63 50.17±6.07 51.83±3.04 51.50±6.00 F=3.09
p=0.048
F<1 F<1
L-theanine 51.50±4.09 58.42±6.34 47.92±6.24 54.75±6.75
Caffeine 55.83±4.65 49.17±6.98 58.42±4.73 57.92±6.80
Combination 59.25±3.12 54.75±6.30 56.92±4.95 57.75±5.73
Jittery (mm) Placebo 12/12 28.92±5.51 17.75±3.86 37.75±6.78 23.00±5.40 F<1 F=1.48
p>0.1
F<1
L-theanine 26.92±3.59 24.25±6.27 36.08±6.36 25.92±6.59
Caffeine 33.33±4.32 27.17±5.33 36.25±5.93 30.92±6.88
Combination 26.50±5.26 26.58±6.40 35.67±6.23 25.08±5.84
Tired (mm) Placebo 12/12 46.25±7.87 54.25±6.70 51.67±6.59 53.33±5.83 F=2.68
p=0.07
F<1 F<1
L-theanine 45.75±6.44 42.83±4.36 45.67±6.91 49.25±6.36
Caffeine 50.92±5.83 53.92±6.41 40.25±4.84 44.67±7.95
Combination 39.08±6.36 49.67±5.88 46.83±6.24 43.83±7.08
Tense (mm) Placebo 12/12 28.50±4.27 24.42±4.89 36.17±6.30 23.42±4.78 F<1 F=1.51
p>0.1
F=1.06
p>0.1L-theanine 34.00±5.56 25.83±5.35 38.83±6.36 22.92±5.65
Caffeine 32.17±4.50 26.08±6.01 35.08±6.14 29.58±6.71
Combination 31.75±6.20 18.67±3.28 32.92±5.72 25.58±5.96
Headache (mm) Placebo 12/12 16.50±6.34 18.00±5.39 28.58±7.11 36.83±7.40 F=1.27
p>0.1
F<1 F=1.12
p>0.1L-theanine 16.00±4.57 20.50±5.93 28.42±6.36 30.83±6.50
Caffeine 19.83±6.58 14.83±3.79 31.25±7.62 27.92±6.85
Combination 12.75±3.59 17.92±4.80 26.25±6.43 21.00±5.55
Overall mood (mm) Placebo 12/12 67.33±4.43 59.83±4.03 59.33±3.70 55.92±5.14 F=3.13
p=0.046
F<1 F=1.38
p>0.1L-theanine 58.50±4.04 66.08±4.08 58.33±4.20 63.67±4.44
Caffeine 61.50±3.98 59.25±4.34 62.00±3.91 64.83±4.92
Combination 66.33±4.02 66.50±3.97 61.17±4.13 68.42±4.02
Mental fatigue (mm) Placebo 12/12 35.83±7.27 30.50±5.59 52.75±7.21 48.25±5.33 F=2.61
p=0.08
F<1 F<1
L-theanine 39.25±5.38 35.00±5.00 54.00±5.36 46.17±5.65
Caffeine 29.25±5.20 33.83±6.34 44.42±7.01 45.17±7.33
Combination 30.58±6.34 31.67±6.13 45.17±6.55 37.33±5.47
Means±SEM values are presented with F and p values from the primary analysis of main effects and treatment×consumer interactions. Significant
measures are shown in bold
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In relation to the behavioural effects, caffeine significantly
reduced choice reaction time, improved Stroop performance
and improved subjective ratings of overall mood. The tasks
affected by caffeine were the latter two completed in the cog-
nitive paradigm, potentially indicating that effects on behav-
iour only became apparent 55 min post-administration.
However, it is interesting to note that these tasks also elicited
the smallest rise in oxy-Hb in all conditions, presumably as a
result of decreased activation over time. Despite effects of
caffeine on oxy-Hb and/or deoxy-Hb during serial subtrac-
tions, simple reaction time and RVIP, there were no corre-
sponding behavioural effects on these tasks. The only other
behavioural effect of treatment was manifested as significantly
less Stroop errors following L-theanine in isolation compared
to the combination treatment. There were no positive effects
on behaviour of combining L-theanine and caffeine. This is
contrary to previous findings (Einother et al. 2010; Haskell
et al. 2008; Kelly et al. 2008; Owen et al. 2008) and is also
somewhat surprising given that the combination showed a
similar but lesser modulation of deoxy-Hb to caffeine, but
did not decrease oxy-Hb (in fact, this was increased during
the final two epochs of the absorption period). The lack of
behavioural effects may be due to the lower doses used here
and the ratio of compounds favouring caffeine as opposed to
L-theanine (see Camfield et al. 2014 for review of behavioural
effects of tea constituents). An overall consumer status effect
indicated that habitual consumers were significantly faster on
the CRT task as compared to non-habitual consumers, irre-
spective of treatment. Non-habitual consumers showed less
reaction time interference on the Stroop task than habitual
consumers. However, examination of means revealed that ha-
bitual consumers were faster than non-habitual consumers in
response to both congruent and incongruent stimuli. The lack
of interactive effects between treatment and consumer status
would seem to indicate net effects of caffeine (Haskell et al.
2005; Hewlett and Smith 2006) rather than reversal of with-
drawal (Rogers et al. 2003). However, it is important to note
that only five of the non-habitual consumers in the current
study reported not consuming any caffeine, and therefore,
the potential impact of caffeine withdrawal in this group, con-
suming an average of 16.7 mg caffeine per day, cannot be
categorically ruled out (James 2014).
In terms of the peripheral effects, the combination treat-
ment was found to increase systolic blood pressure compared
to L-theanine and placebo and increased diastolic blood pres-
sure compared to placebo. The ability of caffeine to raise
blood pressure has been documented previously (James
2004; Rogers et al. 2008; Umemura et al. 2006); therefore,
the rise seen in the present study observed following caffeine
combined with L-theanine, but not caffeine in isolation, is
unexpected. This finding is also in contrast to the findings of
Rogers et al. (2008), who found that when 250 mg caffeine
was combined with 200 mg L-theanine, it was able to attenu-
ate the rise in blood pressure seen following caffeine in isola-
tion. However, Giesbrecht et al. (2010) found that 40 mg caf-
feine combined with 97 mg L-theanine led to significant in-
creases in systolic blood pressure with a trend towards the
same for diastolic. These contrasting effects of caffeine/L-
theanine combinations on blood pressure may be indicative
of differential effects of different doses and ratios on this
parameter.
It is now largely accepted that, at normal dietary levels, the
mechanism of action of caffeine is through antagonism of
adenosine A1 and A2A receptors (Fredholm et al. 1999),
Table 3 Unadjusted baseline and post-dose blood pressure and heart rate readings for each treatment by consumer status
Measure Treatment n Pre-dose baseline score Post-dose score Treatment
effect
Consumer
effect
Treatment×consumer
interaction
Consumers Non-consumers Consumers Non-consumers
Systolic blood
pressure (mmHg)
Placebo 12/12 115.75±3.70 111.83±2.87 114.92±3.47 114.50±1.67 F=5.50
p=0.006
F=1.69
p>0.1
F=2.90
p=0.06L-theanine 120.58±5.07 114.58±3.58 119.67±3.69 111.17±2.94
Caffeine 115.42±2.90 111.08±2.39 119.67±3.88 114.75±2.47
Combination 116.92±3.30 113.33±3.35 124.50±4.07 117.00±2.48
Diastolic Blood
pressure (mmHg)
Placebo 12/12 76.75±2.38 75.33±1.51 75.75±3.95 75.75±2.28 F=3.73
p=0.03
F=1.38
p>0.1
F=1.17
p>0.1L-theanine 78.17±2.00 73.25±1.72 82.25±2.47 76.58±1.75
Caffeine 75.00±1.62 72.33±1.58 83.08±2.67 75.00±2.56
Combination 76.75±2.23 72.92±1.64 81.83±2.88 77.33±1.83
Heart rate (bpm) Placebo 12/12 68.92±2.99 70.33±2.78 62.08±2.65 62.17±2.33 F<1 F<1 F<1
L-theanine 67.92±3.53 70.83±2.74 61.50±2.01 65.00±2.14
Caffeine 65.00±2.54 67.58±2.90 59.25±2.68 63.25±3.59
Combination 68.17±2.89 71.42±2.10 62.17±3.00 63.25±2.05
Means±SEM values are presented with F and p values from the primary analysis of main effects and treatment×consumer interactions. Significant
measures are shown in bold
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increasing release of excitatory neurotransmitters and neuro-
nal firing rate at A1 receptors (Koppelstaetter et al. 2008) and
decreasing blood flow at A2A receptors (Laurienti et al. 2003).
Turning to L-theanine, since the majority of research into the
neuropharmacology of L-theanine has been conducted in an-
imals, the mechanism by which it modulates physiological
and behavioural measures in humans is less well established,
although there is evidence to suggest that L-theanine activates
the ERK/eNOS pathway in vitro, thereby increasing endothe-
lial nitric oxide production, a key mediator in vascular func-
tion (Siamwala et al. 2013), a finding which may play a role in
L-theanine’s previously observed effects on blood pressure
(Rogers et al. 2008). Animal studies have demonstrated that
it can dose-dependently increase levels of dopamine in the rat
striatum (Yokogoshi et al. 1998), increase gamma-
aminobutyric acid (GABA) following intraperitoneal admin-
istration to mice (Kimura and Murata 1971) and modulate
serotonin levels (Yokogoshi et al. 1995, 1998). L-theanine
has also been shown to antagonise glutamate receptors
(Kakuda et al. 2002), a finding which has been linked to neu-
roprotection against cerebral ischemia in mice and gerbils
(Egashira et al. 2004; Kakuda et al. 2000). Given the propen-
sity for consumption of caffeine with L-theanine, further work
is warranted exploring the potential modulatory mechanisms
of L-theanine.
The present study has demonstrated that caffeine and L-
theanine, at doses equivalent to one to two cups of tea, are
capable of modulating cerebral haemodynamics, cognitive
performance, mood and autonomic measures. When com-
bined with 75 mg caffeine, 50 mg L-theanine abolished a
reduction in oxy-Hb observed following 75 mg caffeine in
isolation, with this effect still apparent at the end of the assess-
ment period. Although post-dose testing took place during
peak times for caffeine and L-theanine, ranging from 15 to
120 min (Fredholm et al. 1999) and 32 to 55 min (van der
Pijl et al. 2010) respectively, future studies should aim to
determine the duration of L-theanine’s effects on caffeine,
by extending the post-dose testing period. This study also
demonstrated increases in deoxy-Hb during cognitive tasks,
with effects of caffeine on this measure being exaggerated in
habitual non-consumers of caffeine, providing partial replica-
tion of a previous study showing modulation of the CBF ef-
fects of 75 mg caffeine as a function of habitual caffeine con-
sumption (Kennedy and Haskell 2011). In the current study,
improvements to behaviour observed following 75 mg caf-
feine in isolation, irrespective of consumer status, were lost
when combined with L-theanine. Therefore, the results pre-
sented here do not support combining caffeine with L-
theanine at the doses tested, but it should be noted that when
consumed in the form of tea, there are many other compounds
present with the potential to interact with the two compounds
explored here, and further exploration of these interactions is
warranted. Given the evidence for differential dose effects of
the compounds studied, in terms of behaviour and
haemodynamics, it is also vital that future research explores
the effects of lower doses, equivalent to one cup of tea.
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